IMMUTACE: A Phase 2 Single-Arm, Open-Label Study of Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate-Stage Hepatocellular Carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. An Image-Guided Combination Strategy: Immediate Hepatic Arterial Infusion of Nivolumab Following Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.Cancers · 2026
   Article
2. The State of the Art in Combination Locoregional and Systemic Treatment Strategies for Hepatocellular Carcinoma: Recent Advancements and Future Horizons.Current oncology (Toronto, Ont.) · 2026
   Review
3. Comprehensive treatment of intermediate and advanced primary hepatocellular carcinoma based on transcatheter arterial chemoembolization (Review).Oncology letters · 2025
   Review
4. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.Radiology · 2024
   Review
5. Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.Frontiers in immunology · 2024
   Review
6. First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison.Journal of hepatocellular carcinoma · 2024
   Article
7. Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma.Cancers · 2023
   Review
8. Immunotherapy for advanced or recurrent hepatocellular carcinoma.World journal of gastrointestinal oncology · 2023
   Review
9. Highlights in Hepatocellular Carcinoma From the 2021 European Society for Medical Oncology Congress: Commentary.Gastroenterology & hepatology · 2021
   Article
10. IMMUTACE: A Phase 2 Single-Arm, Open-Label Study of Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate-Stage Hepatocellular Carcinoma.Gastroenterology & hepatology · 2021
    Article
11. Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice.Seminars in interventional radiology · 2020
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.